Abstract
Relapse of AML/MDS after allogeneic SCT is associated with poor outcome. A subset of patients (pts) can be salvaged with DLI or with a second SCT. It was previously speculated that pts given RIC may have a better chance to be salvaged than pts failing high-dose conditioning. We retrospectively analyzed results of 171 SCTs for AML/MDS with iv busulfan (ivBu)-based regimens. 58 pts were eligible for myeloablative conditioning and were given standard ivBuCy. 57 were given RIC consisting of fludarabine (F) and ivBu (FB2, 6.4 mg/kg) and 56 were given a modified myeloablative conditioning consisting of F and full-dose ivBu (FB4, 12.8 mg/kg).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
